APONVIE aprepitant Updated Nov 9
APONVIE is now part of the CorMedix asset acquisition announced November 9, 2026. The deal is expected to close in Q1 2027. For Heron shareholders, the stock's value will increasingly reflect the CRMD shares and NOLs Heron retains post-close rather than APONVIE's standalone commercial trajectory. For CorMedix, APONVIE adds a growing hospital antiemetic to its institutional portfolio.
- APONVIE is the first and only FDA-approved IV formulation of a substance P/NK1 receptor antagonist for postoperative nausea and vomiting (PONV), a large addressable market of ~36 million annual U.S. procedures.
- APONVIE revenue grew 49.3% YoY in Q3 2026, showing strong commercial momentum and market adoption.
- APONVIE was included in the Fifth Consensus Guidelines for PONV management (December 2025), which should support continued adoption by hospital formularies.
- APONVIE faces competition from oral aprepitant (Emend) and other NK1 antagonists, as well as from generic antiemetics used in the hospital setting.
- Heron's overall Q3 2026 revenue declined 7.8% YoY to $35.3M, and the company reported a net loss, indicating the broader business was under pressure before the asset sale.
- The CorMedix asset sale (expected Q1 2027) means Heron shareholders will no longer directly benefit from APONVIE's future revenue growth; the upside is capped at the deal consideration.